Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Dapagliflozin Compared with Glimepiride on Body Composition in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
KCT0003600Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2016
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin, glimepiride, metformin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Jan 2016; status: completed.
02
Drugs
dapagliflozinglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0003600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003600.